
Please try another search
Tissue Regenix Group plc, a medical technology company, develops and commercializes platform technologies in the field of tissue engineering and regenerative medicine in the United States and internationally. It operates through BioSurgery, Orthopaedics & Dental, and GBM-V & Cardiac divisions. The company provides dCELL technology, a soft tissue decellularisation process that removes DNA and cellular material from animal and human soft tissue to repair diseased or damaged body parts; and BioRinse technology, a natural bone filler solution for osteoinductive to stimulate and regenerate native bone growth. In addition, the company provides DermaPure, a decellularised dermal allograft for reinforcement, repair, and replacement of damaged or inadequate integumental tissue and other homologous uses of human integument; and SurgiPure XD, Decellularised porcine dermal reconstructive tissue matrix for the repair of hernias and body wall defects. Further, it offers OrthoPure XT, a scaffold to replace the damaged tissue that will re-populate with the patient’s own cells; ConCelltrate 100, a verified osteoinductive bone matrix; MatrixCellect 100, a demineralised bone matrix (DBM) for orthopaedic; Matrix IQ Dermis, a human-derived dermal graft, which is decellularised to remove cellular components and preserve the biological properties that promote revascularisation, repair, and augmentation of damaged tissue; and Matrix OI FlexIt, a thin pliable demineralised cortical allograft bone sheet. Additionally, the company provides DentalFix, a mineralized particulate allograft that offer osteoconductive properties of natural bone; CardioPure products; Matrix OI 100 DBM for non-structural bone-grafting; Matrix OI Strips and Blocks, a stem cell containment human scaffold; AmnioWorks for ophthalmology and wound covering; and sports medicine products. The company was incorporated in 2006 and is based in Garforth, the United Kingdom.
Name | Age | Since | Title |
---|---|---|---|
David Claiborne Cocke | 55 | 2021 | CFO & Executive Director |
Jonathan M. Glenn | 52 | 2016 | Non-Executive Chairman |
Thomas Carter | - | 2016 | Member of Orthopedic Clinical Advisory Board for US |
David Caborn | - | 2016 | Member of Orthopedic Clinical Advisory Board for US |
Philip Davidson | - | 2016 | Member of Orthopedic Clinical Advisory Board for US |
Brian Phillips | - | 2021 | Independent Non-Executive Director |
Daniel R. Lee | - | 2019 | CEO & Director |
Trevor Michael Phillips | 60 | 2021 | Independent Non-Executive Director |
Jack Farr | - | 2016 | Member of Orthopedic Clinical Advisory Board for US |
Steven Arnoczky | - | 2016 | Member of Orthopedic Clinical Advisory Board for US |
Shervanthi Homer-Vanniasinkam | - | 2016 | Non-Executive Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review